VectorY has appointed Adam Rosenberg as the new Chair of the Board.
VectorY Therapeutics has announced the appointment of Adam Rosenberg as the new Chair of the Board.
Adam brings over 20 years of experience in building and leading life sciences companies, primarily in the neuroscience space.
He replaces Dr Carlo Incerti who is stepping down from the company’s board.
The appointment comes at a pivotal time for VectorY as the company advances towards clinical development with a pipeline of strongly differentiated vectorised antibody treatments for neurodegenerative disorders.
Sander van Deventer, CEO of VectorY, commented: “Adam is a seasoned biotech and independent executive with a proven track record in building successful businesses and teams. I am excited to be working with Adam and our board as VectorY advances to its next phase of growth, from a preclinical to clinical stage company, and as we expand our footprint in the US.”
Adam enthused: “I am delighted to join VectorY at such a pivotal moment in the company’s development. The team has already made significant strides in researching and developing novel treatments with disease-modifying potential for ALS and other neurodegenerative diseases.”
Previously Adam was the founding CEO of Aliada Therapeutics, Athenen Therapeutics and Sionna Therapeutics.
Prior to that, he was President, CEO and member of the Board of Directors of Rodin Therapeutics.